Image

Our unique team of experts brings together experience, passion and a collaborative spirit to deliver the full potential of your gene therapy

LEADERSHIP

Image

Dr Alan Walker

Chief Executive Officer

Alan is Chief Executive Officer of Ryboquin and NanoGenics with a background in marketing and over 49 years of experience in the pharmaceutical industry. Alan believes in getting results through teamwork in business and in research. He has held senior management positions including Managing Director, Regional President and CEO at U.S. pharmaceutical and UK biotechnology companies large and small.

Image

Dr Simon Newman

Chief Scientific Officer

As Chief Scientific Officer of NanoGenics, Simon is responsible for the ongoing development of the in-house product pipeline and the continued development of the LipTide platform. Simon has led oncology drug discovery projects and new company spinouts at Imperial College London for ten years. He has published over 60 peer-reviewed papers, which have been cited over 2000 times. Simon has worked with Ipsen, Sterix, and Oxandia Ltd and was Director of Research for Target Ovarian Cancer.

Image

Ian McDonald

Chief Financial Officer

Ian is an experienced Chief Financial Officer with a 25-year career with SMEs and PLCs in both the manufacturing and service sectors – particularly within life sciences, pharmaceuticals and FMCG. Ian has a successful track record of achievement as a CFO within private equity-backed businesses.

Image

Paul Murray

Executive Chairman

Paul is a chartered accountant with nearly 30 years of experience in the private equity market, having been a director of 3i PLC and a partner in Deutsche Bank’s private equity business. Paul now runs his own private equity fund.

Image

Jonathan Lane

Director of Business Development

With a background in molecular biology, Jonathan has worked in biotechnology for over 20 years. After a short but diverse research career, he moved into patent management and business development/licensing roles before co-founding NanoGenics.

Board of Directors

Paul Murray

Executive Chairman

Paul is a chartered accountant with nearly 30 years of experience in the private equity market, having been a director of 3i PLC and a partner in Deutsche Bank’s private equity business. Paul now runs his own private equity fund.

Dr Alan Walker
Dr Simon Newman
Dr (Prof) Alistair Strachan
Dr (Prof) David Harrison
Ian McDonald
Matthew Benson
Adrian Kirk
Robert Dick

Scientific Advisory Board

Dr (Prof) Alistair Strachan (Chair)

Chair

Alistair formerly served as Head of Operations Global Biotherapeutics Technologies at Pfizer, VP of Licensing & Business Development EMEA at Wyeth and Head of Operations, Neurology and GI Centre of Excellence for Drug Discovery at GSK. He was made an honorary professor by the University of Aberdeen in 2012.

Dr (Prof) David Harrison
Dr Aris Tagalakis
Prof Alexander Mullen
Prof Gordon Jayson
Dr Ian Waddell
Dr Frank Fildes
Dr Simon Newman